Advertisement
Advertisement

LENZ

LENZ logo

LENZ Therapeutics, Inc. Common Stock

6.15
USD
Sponsored
-0.19
-3.00%
Jun 18, 16:00 UTC -4
Closed
exchange

After-Market

6.09

-0.06
-0.98%

LENZ Therapeutics, Inc. Common Stock Profile

About

Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Lenz Therapeutics Inc., formerly known as Graphite Bio Inc., is based in SOUTH SAN FRANCISCO, Calif.

Info & Links

CEO

Evert Schimmelpennink

Headquarters

201 Lomas Santa Fe Dr., Suite 300
Solana Beach, CA 92075, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

https://lenz-tx.com

Auditor

Ernst & Young LLP

Share holders

30

Employees

152

LENZ Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

190.95M

Enterprise Value

166.18M

Enterprise Value/EBITDA(ttm)

-1.41

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.02

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

68.42%

Operating Margin(ttm)

--

Profit Margin(ttm)

-673.07%

Return on Equity(ttm)

-37.47%

Return on Invested Capital(ttm)

-36.08%

Return on Assets(ttm)

-35.13%

Income Statement

Revenue(ttm)

20.99M

Revenue Per Share(ttm)

0.67

Gross Profit(ttm)

19.49M

EBITDA(ttm)3

-117.98M

Net Income Available to Common(ttm)

-109.00M

Diluted EPS(ttm)

-2.81

Share Statistics

Beta (5Y Monthly)

0.66

52-Week Change

-78.76%

S&P 500 52-Week Change

25.68%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

31.35M

Dividend Yield

0.00%

Float4

29.19M

% Held by Insiders

6.90%

% Held by Institutions

54.32%

Balance Sheet

Total Cash(mrq)

258.38M

Total Cash Per Share(mrq)

8.24

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

14.23%

Quick Ratio(mrq)

14.09%

Book Value Per Share(mrq)

9.07

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.40

Free Cash Flow(ytd)

-70.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement